- /
- Supported exchanges
- / US
- / XERS.NASDAQ
Xeris Pharmaceuticals Inc (XERS NASDAQ) stock market data APIs
Xeris Pharmaceuticals Inc Financial Data Overview
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Xeris Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Xeris Pharmaceuticals Inc data using free add-ons & libraries
Get Xeris Pharmaceuticals Inc Fundamental Data
Xeris Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 368 M
- EBITDA: 58 937 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Xeris Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: 0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xeris Pharmaceuticals Inc News
New
Xeris Biopharma (XERS) Adds Menassie M. Taddese To Its Board
Xeris Biopharma Holdings (NasdaqGS:XERS) has appointed Menassie M. Taddese to its Board of Directors. Taddese brings nearly 30 years of global biopharma experience, including senior roles at Viatris a...
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Raises full-year 2026 total revenue guidance to $395 million to ...
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar ...
Xeris (XERS) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President of Investor Relations - Allison Wey Chairman and Chief Executive Officer - John S...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.